Welcome to our dedicated news page for Femasys (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Femasys 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Femasys 's position in the market.
Rhea-AI Summary
Femasys CEO and Founder Kathy Lee-Sepsick meets with Members of Congress to raise awareness of the company and discuss women's healthcare initiatives. The company focuses on addressing unmet needs of women with a portfolio of innovative products. President Biden's executive order for women's health initiatives has spurred interest in Femasys' solutions. The company offers minimally-invasive reproductive products and is developing a permanent birth control solution called FemBloc. Femasys recently announced positive topline data from its FemaSeed pivotal trial, showing a 24% pregnancy rate in women with male factor infertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
-
News
Rhea-AI Summary
Femasys Inc. secures capital after FDA clearance of FemaSeed® to support commercial initiatives, with positive trial data and key appointments. Financially, R&D expenses increased, while sales decreased, resulting in a net loss, but the company expects to fund operations into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.97%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) CEO Kathy Lee-Sepsick and CMO James Liu will discuss infertility treatment options, including FemaSeed®, in a virtual Fireside Chat with Jones Trading Analyst Catherine Novack. The event will focus on ART trends, FemaSeed's role, and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces positive topline data from its FemaSeed Localized Directional Insemination pivotal trial, showing a 24% pregnancy rate in women with severe male factor infertility. This rate is more than double the historic IUI rate, positioning FemaSeed as a cost-effective first-line treatment option. The majority of successful pregnancies occurred after the first FemaSeed procedure, with no new safety concerns reported. With FDA clearance and funding secured until 2025, Femasys is set to launch FemaSeed in the U.S. in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces CEO Kathy Lee-Sepsick and CMO James Liu will join Jones Trading Analyst Catherine Novack in a discussion on infertility treatment options, including FemaSeed®. The event will focus on current trends in assisted reproductive technology and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
-
Rhea-AI Summary
Femasys Inc. announces the first commercial procedure using FemaSeed, an alternative to IVF, aiming to reshape female infertility management. Top-line pivotal data expected in Q1 2024 amidst ongoing uncertainty post-Alabama Supreme Court ruling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
Rhea-AI Summary
Femasys prepares to launch FemaSeed® in the U.S. amidst legal uncertainty after Alabama Supreme Court ruling. The company plans to release top-line data from a pivotal clinical trial in Q1 2024. FemaSeed offers a cost-effective and safe alternative to traditional assisted reproductive methods, aiming to revolutionize fertilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
-
Rhea-AI Summary
Femasys Inc. appoints Richard Spector as chief commercial officer to lead the commercial launch of FemaSeed, a novel solution for infertility, and FemBloc, a non-surgical permanent birth control. Mr. Spector brings 25 years of experience in leading public and private healthcare companies and will be granted 100,000 shares of Femasys common stock as an inducement for his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announced the activation of enrollment for its pivotal FemBloc trial at the University of California, Davis Medical Center. The trial aims to investigate the safety and efficacy of FemBloc, a non-surgical, permanent birth control candidate. This marks the third academic center to participate in the trial, with Dr. Mitchell Creinin as an initial advisor. The trial is designed to address the high unmet need for women seeking permanent birth control, for whom elective surgery remains the only option. Femasys is focused on creating accessible innovative options for women, with a broad portfolio of in-office, accessible solutions and late-stage clinical development for permanent birth control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
Rhea-AI Summary
Femasys Inc. announces the activation of enrollment for its pivotal FemBloc trial at the University of Utah Hospital, led by Dr. Lori Gawron, M.D. The trial is designed to investigate the safety and efficacy of FemBloc, a non-surgical permanent birth control solution. The company is focused on providing accessible solutions for women worldwide, with a broad portfolio of products in late-clinical stage development and FDA-cleared products. The involvement of University of Utah Hospital and Dr. Gawron demonstrates support for FemBloc and its potential to provide improved birth control options for women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
Femasys Inc.
Nasdaq:FEMY
FEMY Rankings
FEMY Stock Data
28.07M
19.87M
7.64%
6.42%
7.88%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SUWANEE
About FEMY
our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t